Kimball Electronics Reports Q1 Results Highlighted by the Return to Top-Line Growth; Company Reiterates Guidance for Fiscal 2027 With Sales Expected at the High End of the Range
Business Wire•04/11/2026•16:05 ET
0
Key Highlights
- ➤Net sales $390.8 million, up 7% year over year
- ➤Medical sales increased 14%, including 9% organic growth
- ➤Operating income fell to $12.4 million from $14.5 million
- ➤Fiscal 2027 sales reiterated at high end of $1,535-$1,560 million range
- ➤Adjusted operating income margin guidance remains 4.4%-4.7% of sales
Expert Statements
Richard D. Phillips, Chief Executive Officer of Kimball Electronics
“I’m encouraged by our first quarter results and solid start to fiscal 2027. Sales increased both sequentially and year-over-year, margins were healthy, and cash conversion days were once again at a multiyear low. The top line benefited from organic sales growth and the contribution from Helvoet Polymer Technologies, our recent tuck-in acquisition in the medical CDMO. The organic growth was in line with expectations and driven by a high single-digit increase in Medical. This growth aligns with our strategic focus to balance the portfolio across the verticals.”
Richard D. Phillips, Chief Executive Officer of Kimball Electronics
“Our excitement for the overall fit and growth opportunities of Helvoet are higher now than ever. With the backdrop of a strong balance sheet, we’re investing in medical growth by integrating Helvoet, ramping operations in Indianapolis, leveraging our capabilities as a full service provider, and unlocking synergies across our global footprint. Fiscal 2027 marks an important milestone in our journey and we are reiterating our guidance for the year with sales expected at the high end of the range, driven by continued strength in Medical.”
Kimball Electronics Reports Q1 Results Highlighted by the Return to Top-Line Growth; Company Reiterates Guidance for Fiscal 2027 With Sales Expected at the High End of the Range
* Net sales of $390.8 million, a 5% increase sequentially and up 7% compared to Q1 fiscal 2026
Get started
Create a free account to read the full story.
